UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 66

Sortiert nach

Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression

The New England journal of medicine, 2020-03, Vol.382 (12), p.1112-1123

2020

Volltextzugriff (PDF)

Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection

The New England journal of medicine, 2020-03, Vol.382 (12), p.1124-1135

2020

Volltextzugriff (PDF)

Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis

AIDS (London), 2021-07, Vol.35 (9), p.1333-1342

2021

Volltextzugriff (PDF)

Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial

The Lancet (British edition), 2011-07, Vol.378 (9787), p.238-246

2011

Volltextzugriff (PDF)

Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials

Journal of acquired immune deficiency syndromes (1999), 2020-12, Vol.85 (4), p.498

2020

Volltextzugriff (PDF)

Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial

The Lancet (British edition), 2011-07, Vol.378 (9787), p.229-237

2011

Volltextzugriff (PDF)

Formulation and pharmacology of long-acting rilpivirine

Current opinion in HIV & AIDS, 2015-07, Vol.10 (4), p.233

2015

Volltextzugriff (PDF)

Lack of Pharmacokinetic Interaction between Rilpivirine and Integrase Inhibitors Dolutegravir and GSK1265744

Antimicrobial Agents and Chemotherapy, 2013-11, Vol.57 (11), p.5472-5477

2013

Volltextzugriff (PDF)

Population Pharmacokinetic Analysis of Darunavir and Tenofovir Alafenamide in HIV-1-Infected Patients on the Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen (AMBER and EMERALD Studies)

The AAPS journal, 2021-06, Vol.23 (4), p.82-82, Article 82

2021

Volltextzugriff (PDF)

Pharmacokinetics of Total and Unbound Etravirine in HIV-1-Infected Pregnant Women

Journal of acquired immune deficiency syndromes (1999), 2016-11, Vol.73 (3), p.268

2016

Volltextzugriff (PDF)

Etravirine in treatment-experienced HIV-1-infected children 1 year to less than 6 years of age

AIDS (London), 2021-07, Vol.35 (9), p.1413-1421

2021

Volltextzugriff (PDF)

Pharmacokinetics, Antiviral Activity, and Safety of Rilpivirine in Pregnant Women with HIV-1 Infection: Results of a Phase 3b, Multicenter, Open-Label Study

Infectious diseases and therapy, 2018-03, Vol.7 (1), p.147-159

2018

Volltextzugriff (PDF)

Practical dosing guidance for the management of clinician-administered injections of long-acting cabotegravir and rilpivirine

Therapeutic Advances in Infectious Disease, 2023-01, Vol.10

2023

Volltextzugriff (PDF)

Impact of Food and Different Meal Types on the Pharmacokinetics of Rilpivirine

Journal of clinical pharmacology, 2013-08, Vol.53 (8), p.834-840

2013

Volltextzugriff (PDF)

Bioequivalence of the Once‐Daily Single‐Tablet Regimen of Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide Compared to Combined Intake of the Separate Agents and the Effect of Food on Bioavailability

Clinical pharmacology in drug development, 2019-05, Vol.8 (4), p.480-491

2019

Volltextzugriff (PDF)

Pharmacological characterization of nucleotide P2Y receptors on endothelial cells of the mouse aorta

British journal of pharmacology, 2005-09, Vol.146 (2), p.288-295

2005

Volltextzugriff (PDF)

Drug Interactions with New and Investigational Antiretrovirals

Clinical pharmacokinetics, 2010, Vol.49 (1), p.67-68

2010

Volltextzugriff (PDF)

Transcription Profiles of Aortic Smooth Muscle Cells from Atherosclerosis-Prone and -Resistant Regions in Young Apolipoprotein E-Deficient Mice before Plaque Development

Journal of vascular research, 2011-01, Vol.48 (1), p.31-42

2011

Volltextzugriff (PDF)

Pharmacokinetic interaction between etravirine or rilpivirine and telaprevir in healthy volunteers: A randomized, two-way crossover trial

Journal of clinical pharmacology, 2014-05, Vol.54 (5), p.563-573

2014

Volltextzugriff (PDF)

The effect of rilpivirine on the pharmacokinetics of methadone in HIV-negative volunteers

Journal of clinical pharmacology, 2014-02, Vol.54 (2), p.133-140

2014

Volltextzugriff (PDF)

Lack of an effect of rilpivirine on the pharmacokinetics of ethinylestradiol and norethindrone in healthy volunteers

International journal of clinical pharmacology and therapeutics, 2014-02, Vol.52 (2), p.118

2014

Volltextzugriff (PDF)

Plaque-associated endothelial dysfunction in apolipoprotein E-deficient mice on a regular diet. Effect of human apolipoprotein AI

Cardiovascular research, 2003-07, Vol.59 (1), p.189-199

2003

Volltextzugriff (PDF)

Etravirine combined with antiretrovirals other than darunavir/ritonavir for HIV-1-infected, treatment-experienced adults: Week 48 results of a phase IV trial

SAGE open medicine, 2017-01, Vol.5, p.2050312116686482-2050312116686482

2017

Volltextzugriff (PDF)

Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial

The Lancet (British edition), 2017-09, Vol.390 (10101), p.1499-1510

2017

Volltextzugriff (PDF)

1 – 25 von 66

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(64)
Mit Volltextzugriff
(52)

Publikationsform

Artikel
(65)
Buchkapitel
(1)

Sprache

Englisch
(66)
Japanisch
(8)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(51)
Science & Technology
(51)
Humans
(38)
Adult
(29)
Rilpivirine
(29)
Female
(27)
Hiv
(24)
Hiv Infections - Drug Therapy
(24)
Infectious Diseases
(24)
Male
(23)
Pharmacokinetics
(22)
Pharmacology & Pharmacy
(22)
Human Immunodeficiency Virus
(20)
Middle Aged
(18)
Anti-Hiv Agents - Adverse Effects
(17)
Antiretroviral Drugs
(17)
Immunology
(15)
Anti-Hiv Agents - Administration & Dosage
(14)
Hiv-1
(14)
Biological And Medical Sciences
(12)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression

Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection

Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis

Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial

Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials

Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial

Formulation and pharmacology of long-acting rilpivirine

Lack of Pharmacokinetic Interaction between Rilpivirine and Integrase Inhibitors Dolutegravir and GSK1265744

Population Pharmacokinetic Analysis of Darunavir and Tenofovir Alafenamide in HIV-1-Infected Patients on the Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen (AMBER and EMERALD Studies)

Pharmacokinetics of Total and Unbound Etravirine in HIV-1-Infected Pregnant Women

Etravirine in treatment-experienced HIV-1-infected children 1 year to less than 6 years of age

Pharmacokinetics, Antiviral Activity, and Safety of Rilpivirine in Pregnant Women with HIV-1 Infection: Results of a Phase 3b, Multicenter, Open-Label Study

Practical dosing guidance for the management of clinician-administered injections of long-acting cabotegravir and rilpivirine

Impact of Food and Different Meal Types on the Pharmacokinetics of Rilpivirine

Bioequivalence of the Once‐Daily Single‐Tablet Regimen of Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide Compared to Combined Intake of the Separate Agents and the Effect of Food on Bioavailability

Pharmacological characterization of nucleotide P2Y receptors on endothelial cells of the mouse aorta

Drug Interactions with New and Investigational Antiretrovirals

Transcription Profiles of Aortic Smooth Muscle Cells from Atherosclerosis-Prone and -Resistant Regions in Young Apolipoprotein E-Deficient Mice before Plaque Development

Pharmacokinetic interaction between etravirine or rilpivirine and telaprevir in healthy volunteers: A randomized, two-way crossover trial

The effect of rilpivirine on the pharmacokinetics of methadone in HIV-negative volunteers

Lack of an effect of rilpivirine on the pharmacokinetics of ethinylestradiol and norethindrone in healthy volunteers

Plaque-associated endothelial dysfunction in apolipoprotein E-deficient mice on a regular diet. Effect of human apolipoprotein AI

Etravirine combined with antiretrovirals other than darunavir/ritonavir for HIV-1-infected, treatment-experienced adults: Week 48 results of a phase IV trial

Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study

Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial

Suchergebnisse filtern